Recent progress in nanotechnology-based novel drug delivery systems in designing of cisplatin for cancer therapy: an overview

Abstract

2019) Recent progress in nanotechnology-based novel drug delivery systems in designing of cisplatin for cancer therapy: an overview, Artificial ABSTRACT Cisplatin cis-(diammine)dichloridoplatinum(II) (CDDP) is the first platinum-based complex approved by the food and drug administration (FDA) of the United States (US). Cisplatin is the first line chemotherapeutic agent used alone or combined with radiations or other anti-cancer agents for a broad range of cancers such as lung, head and neck. Aroplatin TM , Lipoplatin TM and SPI-077 are PEGylated liposomebased nano-formulations that are still under clinical trials. They have many limitations, for example, poor aqueous solubility, drug resistance and toxicities, which can be overcome by encapsulating the cisplatin in Nemours nanocarriers. The extensive literature from different electronic databases covers the different nano-delivery systems that are developed for cisplatin. This review critically emphasizes on the recent advancement, development, innovations and updated literature reported for different carrier systems for CDDP. ARTICLE HISTORY Current status of FDA-approved/under clinical trials CDDP nano-formulationsMany liposomal-based nano-formulations are at the stage of clinical trials. One of under clinical trials drugs, Lipoplatin (Regulon, Inc.), is liposome-based platinum formulation under Phase III clinical trials [11]. It contains a combination of cisplatin (9%) and lipids (91%(w/w)), including soy phosphatidylcholine (SPC-3), cholesterol, dipalmitoyl phosphatidyl glycerol (DPPG) and methoxy-PEG-distearoyl phosphatidyl

Applications and Limitations of Dendrimers in Biomedicine

“…Dendrimers are perfect partners for active pharmaceutical ingredients, due to their structural specificity, which allows the following: (a) inclusion inside the cavities ( Figure 3 a), (b) attachment of bioactive compounds/drug molecules to the functional groups at the periphery of the dendrimer ( Figure 3 b), and (c) both of the above—offering encapsulation (internal cavities) and a support for conjugates (on the surface) ( Figure 3 c). The interaction between drugs and dendrimers is beneficial since it improves solubility, thus improving the absorption and bioavailability of the drug molecule or its cytotoxicity [ 26 , 46 , 47 ].…”

“…A multitude of studies were conducted on the cytotoxicities of different dendrimers [ 26 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 ]. Normal and cancer cell lines of animal and human origin were studied, among which were B14 (Chinese hamster fibroblasts), N2a (mouse neuroblastoma), CHO (Chinese hamster ovary, BRL-3A (rat liver derived cells), H4IIE (rat hepatoma), HepG2 (human liver hepatocellular carcinoma), Caco-2 (colon adenocarcinoma), B16F10 (murine melanoma cells), SW480 (primary adenocarcinoma of colon), U87MG (glioblastoma), hTERT/E6/E7 (human immortalized astrocytes), HaCaT (human epidermal keratinocytes), SK-Mel-28 (human melanoma), MDA-MB-231 (breast cancer), SKOV3 (human ovarian carcinoma), HepG2 (human liver hepatocellular carcinoma) and MCF7 (human breast adenocarcinoma) [ 40 , 250 ].…”

Elevated levels of miR-483-5p in oocytes aggravates premature ovarian insufficiency induced by CDDP by targeting the FKBP4

“…Chemotherapy have radically increased long-term survival of young cancer patients, however, major side effects are premature ovarian insu ciency and infertility [5]. Cisdiaminedichloroplatinum (cisplatin, CDDP) is a rst-line chemotherapeutic drug that is widely used to treat a range of human tumors, including bladder, head and neck, lung, ovarian, and testicular cancers [6][7][8][9]. A previous study showed that CDDP could induce POI injury due to the excessive activation of dormant primordial follicles via the PTEN/AKT/ FOXO3a pathway [10][11][12].…”

Elevated levels of miR-483-5p in oocytes aggravates premature ovarian insufficiency induced by CDDP by targeting the FKBP4

“…CDDP is a first-line chemotherapeutic drug that is widely used to treat a range of tumors, including germ cell tumors, particularly ovarian cancer. [3,4] A previous study showed that CDDP could induce POI injury due to the excessive activation of dormant primordial follicles via the PTEN/AKT/ FOXO3a pathway. [5,6] Furthermore, we previously reported that CDDP-induced endoplasmic reticulum stress (ERS) could promote autophagy and apoptosis in granulosa cells, thus, resulting in excessive follicle loss and endocrine disorders.…”